<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38570429</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway.</ArticleTitle><Pagination><StartPage>8921</StartPage><EndPage>8927</EndPage><MedlinePgn>8921-8927</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-024-04157-w</ELocationID><Abstract><AbstractText>The biological substrate of persistent post-COVID-19 hyposmia is still unclear. However, as many neurodegenerative diseases present with smell impairment at onset, it may theoretically reflect degeneration within the central olfactory circuits. However, no data still exist regarding the post-COVID-19 patients. As the olfactory neurons (ONs) mirror pathological changes in the brain, allowing for tracking the underlying molecular events, here, we performed a broad analysis of ONs from patients with persistent post-COVID-19 OD to identify traces of potential neurodegeneration. ONs were collected through the non-invasive brushing of the olfactory mucosa from ten patients with persistent post-COVID-19 hyposmia (lasting&#x2009;&gt;&#x2009;6&#xa0;months after infection) and ten age/sex-matched controls. Immunofluorescence staining for protein quantification and RT-PCR for gene expression levels were combined to measure ONs markers of &#x3b1;-synuclein, amyloid-&#x3b2;, and tau pathology, axonal injury, and mitochondrial network. Patients and controls had similar ONs levels of oligomeric &#x3b1;-synuclein, amyloid-&#x3b2; peptide, tau protein, neurofilament light chain (NfL), cytochrome C oxidase subunit 3 (COX3), and the heat shock protein 60 (HSP60). Our findings thus did not provide evidence for synucleinopathy and amyloid-&#x3b2; mismetabolism or gross traces of neuronal injury and mitochondrial dysfunction within the olfactory system in the early phase of persistent post-COVID-19 hyposmia.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schirinzi</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy. t.schirinzi@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maftei</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurizi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetta</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bovenzi</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bissacco</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascioli</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boffa</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Certo</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabanella</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Girolamo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercuri</LastName><ForeName>Nicola Biagio</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passali</LastName><ForeName>Francesco Maria</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lattanzi</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severini</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SEED PNR (2021) "PROKINETICIN 2: a new potenzial neuroinflammatory biomarker in Alzheimer disease"</GrantID><Agency>Sapienza Universit&#xe0; di Roma</Agency><Country/></Grant><Grant><GrantID>DSB.AD006.371 "INVECCHIAMENTO ATTIVO E IN SALUTE (FOE 2022)</GrantID><Agency>Ministero dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="Y">Anosmia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009833" MajorTopicYN="Y">Olfactory Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009831" MajorTopicYN="N">Olfactory Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018034" MajorTopicYN="N">Olfactory Receptor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hyposmia</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Olfactory dysfunction</Keyword><Keyword MajorTopicYN="N">Olfactory neurons</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38570429</ArticleId><ArticleId IdType="pmc">PMC11496343</ArticleId><ArticleId IdType="doi">10.1007/s12035-024-04157-w</ArticleId><ArticleId IdType="pii">10.1007/s12035-024-04157-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schirinzi T, Landi D, Liguori C (2020) COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol. 10.1007/s00415-020-10131-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450256</ArticleId><ArticleId IdType="pubmed">32852580</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z (2022) Long-term neurologic outcomes of COVID-19. Nat Med 28(11):2406&#x2013;2415. 10.1038/s41591-022-02001-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Liu J, Lin J, Shang H (2022) COVID-19 and risk of neurodegenerative disorders: a mendelian randomization study. Transl Psychiatry 12(1):283. 10.1038/s41398-022-02052-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9281279</ArticleId><ArticleId IdType="pubmed">35835752</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL (2022) Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health. Trends Mol Med 28:781&#x2013;794. 10.1016/J.MOLMED.2022.06.005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212891</ArticleId><ArticleId IdType="pubmed">35810128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJ, Chan YH, Teo NWY, Charn TC, See A, Xu S, Chapurin N, Chandra RK, Chowdhury N, Butowt R, von Bartheld CS, Kumar BN, Hopkins C, Toh ST (2022) Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 378:e069503. 10.1136/bmj-2021-069503. Erratum in: BMJ. 2022 Aug 9;378:o1939</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Lattanzi R, Maftei D et al (2022) Substance P and prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction. Brain Behav Immun 108:302&#x2013;308. 10.1016/J.BBI.2022.12.017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9760596</ArticleId><ArticleId IdType="pubmed">36549578</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito F, Cirillo M, De Micco R et al (2022) Olfactory loss and brain connectivity after COVID-19. Hum Brain Mapp 43:1548&#x2013;1560. 10.1002/HBM.25741</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886650</ArticleId><ArticleId IdType="pubmed">35083823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kov&#xe1;cs T (2004) Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Res Rev 3:215&#x2013;232. 10.1016/j.arr.2003.10.003</Citation><ArticleIdList><ArticleId IdType="pubmed">15177056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay LM (2022) Neuroscience of disease: COVID-19 and olfactory dysfunction: a looming wave of dementia? J Neurophysiol 128:436. 10.1152/JN.00255.2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377782</ArticleId><ArticleId IdType="pubmed">35894511</ArticleId></ArticleIdList></Reference><Reference><Citation>Brozzetti L, Sacchetto L, Cecchini MP, Avesani A, Perra D, Bongianni M, Portioli C, Scupoli M, Ghetti B, Monaco S, Buffelli M, Zanusso G (2020) Neurodegeneration-associated proteins in human olfactory neurons collected by nasal brushing. Front Neurosci 14:145. 10.3389/fnins.2020.00145</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066258</ArticleId><ArticleId IdType="pubmed">32194369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Maftei D, Passali FM et al (2022) Olfactory neuron prokineticin-2 as a potential target in Parkinson&#x2019;s disease. Ann Neurol. 10.1002/ANA.26526</Citation><ArticleIdList><ArticleId IdType="pubmed">36218142</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghammer P (2023) The brain-first vs. body-first model of Parkinson&#x2019;s disease with comparison to alternative models. J Neural Transm 130:737&#x2013;753. 10.1007/s00702-023-02633-66</Citation><ArticleIdList><ArticleId IdType="pubmed">37062013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubeda-Ba&#xf1;on I, Saiz-Sanchez D, Flores-Cuadrado A et al (2020) The human olfactory system in two proteinopathies: alzheimer&#x2019;s and parkinson&#x2019;s diseases. Transl Neurodegener 9:22. 10.1186/s40035-020-00200-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271529</ArticleId><ArticleId IdType="pubmed">32493457</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy C (2019) Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol 15:11&#x2013;24. 10.1038/s41582-018-0097-5</Citation><ArticleIdList><ArticleId IdType="pubmed">30532084</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghallab I, Reyes-Ruiz JM, Abulnaja K et al (2018) Epitomic characterization of the specificity of the anti-amyloid A monoclonal antibodies 6E10 and 4G8. J Alzheimer&#x2019;s Dis 66:1235&#x2013;1244. 10.3233/JAD-180582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294585</ArticleId><ArticleId IdType="pubmed">30412489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Lee EB, Moberg PJ et al (2010) Olfactory epithelium amyloid-&#x3b2; and PHFtau pathology in Alzheimer&#x2019;s disease NIH public access. Ann Neurol 67:462&#x2013;469. 10.1002/ana.21910</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864948</ArticleId><ArticleId IdType="pubmed">20437581</ArticleId></ArticleIdList></Reference><Reference><Citation>Son G, Yoo SJ, Kang S et al (2021) Region-specific amyloid-&#x3b2; accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice. Alz Res Therapy 13:4. 10.1186/s13195-020-00730-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784287</ArticleId><ArticleId IdType="pubmed">33397474</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA (2006) Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 25:265&#x2013;271</Citation><ArticleIdList><ArticleId IdType="pubmed">17140156</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Abdelhak A, Foschi M et al (2023) The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146:421&#x2013;437. 10.1093/BRAIN/AWAC328</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494370</ArticleId><ArticleId IdType="pubmed">36083979</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto IC, Fontanesi F, Liu J, Barrientos A (2012) Biogenesis and assembly of eukaryotic cytochrome c oxidase catalytic core. Biochim Biophys Acta 1817(6):883&#x2013;897. 10.1016/j.bbabio.2011.09.005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262112</ArticleId><ArticleId IdType="pubmed">21958598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MY, Hartl FU, Norwich AL (1990) The mitochondrial chaperonin hsp60 is required for its own assembly. Nature 348(6300):455&#x2013;458. 10.1038/348455a0</Citation><ArticleIdList><ArticleId IdType="pubmed">1978929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Maftei D, Grillo P et al (2023) Olfactory neuron substance P is overexpressed in Parkinson&#x2019;s disease reflecting gut dysfunction. Mov Disord. 10.1002/MDS.29433</Citation><ArticleIdList><ArticleId IdType="pubmed">37157902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirassa P, Schirinzi T, Raspa M et al (2021) What substance P might tell us about the prognosis and mechanism of Parkinson&#x2019;s disease? Neurosci Biobehav Rev 131:899&#x2013;911. 10.1016/J.NEUBIOREV.2021.10.008</Citation><ArticleIdList><ArticleId IdType="pubmed">34653503</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Maftei D, Ralli M et al (2021) Serum substance P is increased in Parkinson&#x2019;s disease and correlates with motor impairment. Mov Disord. 10.1002/MDS.28824</Citation><ArticleIdList><ArticleId IdType="pubmed">34623702</ArticleId></ArticleIdList></Reference><Reference><Citation>Maftei D, Schirinzi T, Mercuri NB, Lattanzi R, Severini C (2022) Potential clinical role of prokineticin 2 (PK2) In: neurodegenerative diseases. Curr Neuropharmacol 20(11):2019&#x2013;2023. 10.2174/1570159X20666220411084612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886845</ArticleId><ArticleId IdType="pubmed">35410604</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Maftei D, Pieri M, Bernardini S, Mercuri NB, Lattanzi R, Severini C (2021) Increase of prokineticin-2 in serum of patients with parkinson's disease. Mov Disord 36(4):1031&#x2013;1033. 10.1002/mds.28458</Citation><ArticleIdList><ArticleId IdType="pubmed">33404134</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>